Amedisys (AMED)
(Real Time Quote from BATS)
$90.99 USD
-0.17 (-0.19%)
Updated Apr 24, 2024 11:18 AM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
AMED 90.99 -0.17(-0.19%)
Will AMED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMED
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Here's Why Amedisys (AMED) is a Strong Value Stock
AMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Amedisys (AMED) is a Strong Value Stock
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
Other News for AMED
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
DOJ case against UnitedHealth could take years to resolve, says BoA
Amedisys price target raised by $3 at RBC Capital, here's why
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)
UnitedHealth deal for Amedisys likely to close despite report of DOJ scrutiny - analyst